MedTrace Logo

Effectivity of Postpartum Dexamethasone for Women With Class I HELLP Syndrome

NCT00711841 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2019-06-06

No results posted yet for this study

Summary

Corticotherapy accelerates maternal postpartum recovery in women with class I HELLP syndrome. The benefit of faster and better recovery would be observed in fewer complications, less utilization of blood products and shorter hospital stay.

Conditions

  • HELLP Syndrome

Interventions

DRUG

dexamethasone

Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours

DRUG

Placebo

Saline solution, 2 mL, intravenous, every 12 hours, for 48 hours

DRUG

dexamethasone

dexamethasone, 10mg, 2 mL, intravenous solution, every 12 hours , for 48 hours

Sponsors & Collaborators

  • Instituto Materno Infantil Prof. Fernando Figueira

    lead OTHER

Principal Investigators

  • Leila Katz, pHD · IMIP

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2019-06-30
Completion
2019-06-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00711841 on ClinicalTrials.gov